Holen Sie sich die Stockscreener-App
4.7683
3.83%
-0.1917
Schlusskurs vom Vortag:
$4.96
Offen:
$4.902
24-Stunden-Volumen:
12.92M
Relative Volume:
0.45
Marktkapitalisierung:
$2.49B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-3.0763
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
+2.14%
1M Leistung:
+9.40%
6M Leistung:
-25.82%
1J Leistung:
-36.65%
1-Tages-Spanne:
$4.76
$4.96
1-Wochen-Bereich:
$4.35
$5.24
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.775 | 2.58B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.19 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.04 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharma director Gibson sells $178,800 in stock - Investing.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 10.8%Here's Why - MarketBeat
Biotech Stocks To Keep An Eye OnJanuary 22nd - MarketBeat
Recursion Shines at J.P. Morgan Healthcare Conference - StocksToTrade
Recursion Pharmaceuticals Boosts Visibility With J.P. Morgan Conference - timothysykes.com
How Do Investors Really Feel About Recursion Pharmaceuticals Inc? - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory - Insider Monkey
JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects - Yahoo Finance
Here’s what JP Morgan thinks about Recursion Pharmaceuticals (RXRX) - MSN
Is Meta Stock a Buy Going Into 2026? - AOL.com
Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness - simplywall.st
Sumitomo Mitsui Trust Group Inc. Sells 701,887 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? - Yahoo Finance
Assessing Whether Recursion Pharmaceuticals (RXRX) Looks Undervalued After Recent Trading Volatility - Yahoo Finance
2 AI stocks to buy in 2026, and 1 to avoid - MSN
2 AI Stocks to Buy in 2026, and 1 to Avoid - Finviz
Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates (NASDAQ:RXRX) - Seeking Alpha
Assessing Recursion Pharmaceuticals (RXRX) Valuation After JP Morgan Update And REC-4881 Clinical Milestones - Sahm
Recursion Pharmaceuticals (RXRX) stock drops despite market gains: Important facts to note - MSN
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
How Recursion’s AI Drug Platform Progress And Extended Runway At Recursion Pharmaceuticals (RXRX) Has Changed Its Investment Story - simplywall.st
Recursion Pharmaceuticals patents PIKfyve inhibitors - BioWorld MedTech
How does Recursion Pharmaceuticals Inc score in quality rankingsStop Loss & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside Amidst Biotechnology Challenges - DirectorsTalk Interviews
Market Outlook: Is Recursion Pharmaceuticals Inc stock overvalued by current metrics2025 Retail Activity & Safe Entry Momentum Tips - Bộ Nội Vụ
Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus - TechStock²
Why Recursion Pharmaceuticals Stock Is Quietly Climbing - TipRanks
Recursion Updates AI Drug Platform, Financial Outlook at JPM - TipRanks
Recursion Pharmaceuticals, Inc. Releases Updated Investor Presentation - TradingView — Track All Markets
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Will Recursion Pharmaceuticals Inc. stock benefit from infrastructure spendingStock Surge & Detailed Earnings Play Alerts - ulpravda.ru
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - sharewise.com
Insider Sell: Blake Borgeson Sells 220,000 Shares of Recursion P - GuruFocus
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares - MarketBeat
Recursion Pharmaceuticals Insider Sold Shares Worth $959,200, According to a Recent SEC Filing - MarketScreener
Can Recursion Pharmaceuticals Inc. stock surprise with earnings upsideJuly 2025 Macro Moves & Free Community Consensus Stock Picks - ulpravda.ru
Aug Setups: How Recursion Pharmaceuticals Inc. stock performs after earningsJuly 2025 Opening Moves & Safe Entry Momentum Tips - ulpravda.ru
Recursion pharma director Gibson sells $170k in shares By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates - Finviz
Recursion’s Stock Surge: An Opportunity? - StocksToTrade
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates - Insider Monkey
Recursion Pharmaceuticals Stock Surges: What’s Happening? - timothysykes.com
RXRX Stock’s Impressive Surge: A Closer Look - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 10.7% After Positive REC-4881 Trial Data And Rising Analyst Focus - simplywall.st
Recursion Pharmaceuticals Inc Stock Analysis and ForecastLow Risk Investment Ideas & AI-Based Insights for Consistent Profits - earlytimes.in
Recursion Pharmaceuticals, Inc. (RXRX) Investor Outlook: Uncovering a 60% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - AOL.com
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) Mispriced After Volatile Share Performance And Ongoing Tech Partnerships - simplywall.st
JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline - MSN
Should J.P. Morgan’s REC-4881 Upgrade and TUPELO Data Require Action From Recursion (RXRX) Investors? - Yahoo Finance
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.31%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):